Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 422

1.

Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability.

Dubrovskaya V, Tran K, Ozorowski G, Guenaga J, Wilson R, Bale S, Cottrell CA, Turner HL, Seabright G, O'Dell S, Torres JL, Yang L, Feng Y, Leaman DP, Vázquez Bernat N, Liban T, Louder M, McKee K, Bailer RT, Movsesyan A, Doria-Rose NA, Pancera M, Karlsson Hedestam GB, Zwick MB, Crispin M, Mascola JR, Ward AB, Wyatt RT.

Immunity. 2019 Nov 19;51(5):915-929.e7. doi: 10.1016/j.immuni.2019.10.008. Epub 2019 Nov 12.

2.

Novel vaccine technologies for the 21st century.

Mascola JR, Fauci AS.

Nat Rev Immunol. 2019 Nov 11. doi: 10.1038/s41577-019-0243-3. [Epub ahead of print] No abstract available.

PMID:
31712767
3.

Extensive dissemination and intraclonal maturation of HIV Env vaccine-induced B cell responses.

Phad GE, Pushparaj P, Tran K, Dubrovskaya V, Àdori M, Martinez-Murillo P, Vázquez Bernat N, Singh S, Dionne G, O'Dell S, Bhullar K, Narang S, Sorini C, Villablanca EJ, Sundling C, Murrell B, Mascola JR, Shapiro L, Pancera M, Martin M, Corcoran M, Wyatt RT, Karlsson Hedestam GB.

J Exp Med. 2019 Nov 8. pii: jem.20191155. doi: 10.1084/jem.20191155. [Epub ahead of print]

PMID:
31704807
4.

Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants.

Cunningham CK, McFarland EJ, Morrison RL, Capparelli EV, Safrit JT, Mofenson LM, Mathieson B, Valentine ME, Perlowski C, Smith B, Hazra R, Purdue L, Muresan P, Harding PA, Mbengeranwa T, Robinson LG, Wiznia A, Theron G, Lin B, Bailer RT, Mascola JR, Graham BS; IMPAACT P1112 team.

J Infect Dis. 2019 Nov 4. pii: jiz532. doi: 10.1093/infdis/jiz532. [Epub ahead of print]

PMID:
31681963
5.

Multiple roles for HIV broadly neutralizing antibodies.

Haynes BF, Burton DR, Mascola JR.

Sci Transl Med. 2019 Oct 30;11(516). pii: eaaz2686. doi: 10.1126/scitranslmed.aaz2686. Review.

PMID:
31666399
6.

Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates.

Rawi R, Mall R, Shen CH, Farney SK, Shiakolas A, Zhou J, Bensmail H, Chun TW, Doria-Rose NA, Lynch RM, Mascola JR, Kwong PD, Chuang GY.

Sci Rep. 2019 Oct 11;9(1):14696. doi: 10.1038/s41598-019-50635-w.

7.

Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals.

Blazkova J, Refsland EW, Clarridge KE, Shi V, Justement JS, Huiting ED, Gittens KR, Chen X, Schmidt SD, Liu C, Doria-Rose N, Mascola JR, Heredia A, Moir S, Chun TW.

J Clin Invest. 2019 Nov 1;129(11):4832-4837. doi: 10.1172/JCI125955.

8.

Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk.

Neidich SD, Fong Y, Li SS, Geraghty DE, Williamson BD, Young WC, Goodman D, Seaton KE, Shen X, Sawant S, Zhang L, deCamp AC, Blette BS, Shao M, Yates NL, Feely F, Pyo CW, Ferrari G; HVTN 505 Team, Frank I, Karuna ST, Swann EM, Mascola JR, Graham BS, Hammer SM, Sobieszczyk ME, Corey L, Janes HE, McElrath MJ, Gottardo R, Gilbert PB, Tomaras GD.

J Clin Invest. 2019 Nov 1;129(11):4838-4849. doi: 10.1172/JCI126391.

9.

Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields.

Gorman J, Mason RD, Nettey L, Cavett N, Chuang GY, Peng D, Tsybovsky Y, Verardi R, Nguyen R, Ambrozak D, Biris K, LaBranche CC, Ramesh A, Schramm CA, Zhou J, Bailer RT, Kepler TB, Montefiori DC, Shapiro L, Douek DC, Mascola JR, Roederer M, Kwong PD.

Immunity. 2019 Oct 15;51(4):724-734.e4. doi: 10.1016/j.immuni.2019.09.007. Epub 2019 Oct 2.

PMID:
31586542
10.

Longitudinal antibody responses in people who inject drugs infected with similar HIV strains.

Redd AD, Doria-Rose NA, Weiner JA, Nason M, Seivers M, Schmidt SD, Laeyendecker O, Martens C, Bruno D, Keele BF, Raju N, Georgiev IS, Lamers SL, Astemborski J, Kirk GD, Mascola JR, Ackerman ME, Mehta SH, Quinn TC.

J Infect Dis. 2019 Oct 4. pii: jiz503. doi: 10.1093/infdis/jiz503. [Epub ahead of print]

PMID:
31581292
11.

Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies.

LaBranche CC, Henderson R, Hsu A, Behrens S, Chen X, Zhou T, Wiehe K, Saunders KO, Alam SM, Bonsignori M, Borgnia MJ, Sattentau QJ, Eaton A, Greene K, Gao H, Liao HX, Williams WB, Peacock J, Tang H, Perez LG, Edwards RJ, Kepler TB, Korber BT, Kwong PD, Mascola JR, Acharya P, Haynes BF, Montefiori DC.

PLoS Pathog. 2019 Sep 17;15(9):e1008026. doi: 10.1371/journal.ppat.1008026. eCollection 2019 Sep.

12.

A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge.

Pegu A, Borate B, Huang Y, Pauthner MG, Hessell AJ, Julg B, Doria-Rose NA, Schmidt SD, Carpp LN, Cully MD, Chen X, Shaw GM, Barouch DH, Haigwood NL, Corey L, Burton DR, Roederer M, Gilbert PB, Mascola JR, Huang Y.

Cell Host Microbe. 2019 Sep 11;26(3):336-346.e3. doi: 10.1016/j.chom.2019.08.014.

PMID:
31513771
13.

Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases.

Blackman MA, Marchionni MA, Gilly J, Hepburn M, Innis BL, Barrett ADT, Kester KE, Mascola JR, Cummings JF, Monath TP, Cassetti MC, Kim JH, Saville M, Thomas SJ.

Vaccine. 2019 Oct 8;37(43):6248-6254. doi: 10.1016/j.vaccine.2019.08.061. Epub 2019 Sep 6.

PMID:
31500964
14.

Comparison of adjuvants to optimize influenza neutralizing antibody responses.

Rudicell RS, Garinot M, Kanekiyo M, Kamp HD, Swanson K, Chou TH, Dai S, Bedel O, Simard D, Gillespie RA, Yang K, Reardon M, Avila LZ, Besev M, Dhal PK, Dharanipragada R, Zheng L, Duan X, Dinapoli J, Vogel TU, Kleanthous H, Mascola JR, Graham BS, Haensler J, Wei CJ, Nabel GJ.

Vaccine. 2019 Sep 30;37(42):6208-6220. doi: 10.1016/j.vaccine.2019.08.030. Epub 2019 Sep 5.

PMID:
31493950
15.

Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial.

Gaudinski MR, Houser KV, Doria-Rose NA, Chen GL, Rothwell RSS, Berkowitz N, Costner P, Holman LA, Gordon IJ, Hendel CS, Kaltovich F, Conan-Cibotti M, Gomez Lorenzo M, Carter C, Sitar S, Carlton K, Gall J, Laurencot C, Lin BC, Bailer RT, McDermott AB, Ko SY, Pegu A, Kwon YD, Kwong PD, Namboodiri AM, Pandey JP, Schwartz R, Arnold F, Hu Z, Zhang L, Huang Y, Koup RA, Capparelli EV, Graham BS, Mascola JR, Ledgerwood JE; VRC 605 study team.

Lancet HIV. 2019 Oct;6(10):e667-e679. doi: 10.1016/S2352-3018(19)30181-X. Epub 2019 Aug 28.

PMID:
31473167
16.

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.

Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B.

Cell Host Microbe. 2019 Aug 14;26(2):296. doi: 10.1016/j.chom.2019.07.016. No abstract available.

17.

A proof of concept for structure-based vaccine design targeting RSV in humans.

Crank MC, Ruckwardt TJ, Chen M, Morabito KM, Phung E, Costner PJ, Holman LA, Hickman SP, Berkowitz NM, Gordon IJ, Yamshchikov GV, Gaudinski MR, Kumar A, Chang LA, Moin SM, Hill JP, DiPiazza AT, Schwartz RM, Kueltzo L, Cooper JW, Chen P, Stein JA, Carlton K, Gall JG, Nason MC, Kwong PD, Chen GL, Mascola JR, McLellan JS, Ledgerwood JE, Graham BS; VRC 317 Study Team.

Science. 2019 Aug 2;365(6452):505-509. doi: 10.1126/science.aav9033.

PMID:
31371616
18.

Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin.

Andrews SF, Chambers MJ, Schramm CA, Plyler J, Raab JE, Kanekiyo M, Gillespie RA, Ransier A, Darko S, Hu J, Chen X, Yassine HM, Boyington JC, Crank MC, Chen GL, Coates E, Mascola JR, Douek DC, Graham BS, Ledgerwood JE, McDermott AB.

Immunity. 2019 Aug 20;51(2):398-410.e5. doi: 10.1016/j.immuni.2019.06.024. Epub 2019 Jul 23.

PMID:
31350180
19.

Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization.

Kong R, Duan H, Sheng Z, Xu K, Acharya P, Chen X, Cheng C, Dingens AS, Gorman J, Sastry M, Shen CH, Zhang B, Zhou T, Chuang GY, Chao CW, Gu Y, Jafari AJ, Louder MK, O'Dell S, Rowshan AP, Viox EG, Wang Y, Choi CW, Corcoran MM, Corrigan AR, Dandey VP, Eng ET, Geng H, Foulds KE, Guo Y, Kwon YD, Lin B, Liu K, Mason RD, Nason MC, Ohr TY, Ou L, Rawi R, Sarfo EK, Schön A, Todd JP, Wang S, Wei H, Wu W; NISC Comparative Sequencing Program, Mullikin JC, Bailer RT, Doria-Rose NA, Karlsson Hedestam GB, Scorpio DG, Overbaugh J, Bloom JD, Carragher B, Potter CS, Shapiro L, Kwong PD, Mascola JR.

Cell. 2019 Jul 25;178(3):567-584.e19. doi: 10.1016/j.cell.2019.06.030.

20.

Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations.

Han Q, Jones JA, Nicely NI, Reed RK, Shen X, Mansouri K, Louder M, Trama AM, Alam SM, Edwards RJ, Bonsignori M, Tomaras GD, Korber B, Montefiori DC, Mascola JR, Seaman MS, Haynes BF, Saunders KO.

Nat Commun. 2019 Jul 1;10(1):2898. doi: 10.1038/s41467-019-10899-2.

21.

Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope.

Schoofs T, Barnes CO, Suh-Toma N, Golijanin J, Schommers P, Gruell H, West AP Jr, Bach F, Lee YE, Nogueira L, Georgiev IS, Bailer RT, Czartoski J, Mascola JR, Seaman MS, McElrath MJ, Doria-Rose NA, Klein F, Nussenzweig MC, Bjorkman PJ.

Immunity. 2019 Jun 18;50(6):1513-1529.e9. doi: 10.1016/j.immuni.2019.04.014. Epub 2019 May 21.

22.

A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates.

Ko SY, Akahata W, Yang ES, Kong WP, Burke CW, Honnold SP, Nichols DK, Huang YS, Schieber GL, Carlton K, DaSilva L, Traina-Dorge V, Vanlandingham DL, Tsybovsky Y, Stephens T, Baxa U, Higgs S, Roy CJ, Glass PJ, Mascola JR, Nabel GJ, Rao SS.

Sci Transl Med. 2019 May 15;11(492). pii: eaav3113. doi: 10.1126/scitranslmed.aav3113.

PMID:
31092692
23.

CD8β Depletion Does Not Prevent Control of Viral Replication or Protection from Challenge in Macaques Chronically Infected with a Live Attenuated Simian Immunodeficiency Virus.

Sutton MS, Ellis-Connell A, Balgeman AJ, Barry G, Weiler AM, Hetzel SJ, Zhou Y, Lau-Kilby AW, Mason RD, Biris KK, Mascola JR, Sullivan NJ, Roederer M, Friedrich TC, O'Connor SL.

J Virol. 2019 Jul 17;93(15). pii: e00537-19. doi: 10.1128/JVI.00537-19. Print 2019 Aug 1.

PMID:
31092584
24.

Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaques.

Calenda G, Frank I, Arrode-Brusés G, Pegu A, Wang K, Arthos J, Cicala C, Rogers KA, Shirreff L, Grasperge B, Blanchard JL, Maldonado S, Roberts K, Gettie A, Villinger F, Fauci AS, Mascola JR, Martinelli E.

PLoS Pathog. 2019 May 13;15(5):e1007776. doi: 10.1371/journal.ppat.1007776. eCollection 2019 May.

25.

Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.

Crowell TA, Colby DJ, Pinyakorn S, Sacdalan C, Pagliuzza A, Intasan J, Benjapornpong K, Tangnaree K, Chomchey N, Kroon E, de Souza MS, Tovanabutra S, Rolland M, Eller MA, Paquin-Proulx D, Bolton DL, Tokarev A, Thomas R, Takata H, Trautmann L, Krebs SJ, Modjarrad K, McDermott AB, Bailer RT, Doria-Rose N, Patel B, Gorelick RJ, Fullmer BA, Schuetz A, Grandin PV, O'Connell RJ, Ledgerwood JE, Graham BS, Tressler R, Mascola JR, Chomont N, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV397 Study Group.

Lancet HIV. 2019 May;6(5):e297-e306. doi: 10.1016/S2352-3018(19)30053-0. Epub 2019 Apr 15.

PMID:
31000477
26.

Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting.

Cheng C, Xu K, Kong R, Chuang GY, Corrigan AR, Geng H, Hill KR, Jafari AJ, O'Dell S, Ou L, Rawi R, Rowshan AP, Sarfo EK, Sastry M, Saunders KO, Schmidt SD, Wang S, Wu W, Zhang B, Doria-Rose NA, Haynes BF, Scorpio DG, Shapiro L, Mascola JR, Kwong PD.

PLoS One. 2019 Apr 17;14(4):e0215163. doi: 10.1371/journal.pone.0215163. eCollection 2019.

27.

Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses.

Kanekiyo M, Joyce MG, Gillespie RA, Gallagher JR, Andrews SF, Yassine HM, Wheatley AK, Fisher BE, Ambrozak DR, Creanga A, Leung K, Yang ES, Boyoglu-Barnum S, Georgiev IS, Tsybovsky Y, Prabhakaran MS, Andersen H, Kong WP, Baxa U, Zephir KL, Ledgerwood JE, Koup RA, Kwong PD, Harris AK, McDermott AB, Mascola JR, Graham BS.

Nat Immunol. 2019 Jun;20(6):765. doi: 10.1038/s41590-019-0395-0.

PMID:
30980067
28.

Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes.

O'Brien SP, Swanstrom AE, Pegu A, Ko SY, Immonen TT, Del Prete GQ, Fennessey CM, Gorman J, Foulds KE, Schmidt SD, Doria-Rose N, Williamson C, Hatziioannou T, Bieniasz PD, Li H, Shaw GM, Mascola JR, Koup RA, Kwong PD, Lifson JD, Roederer M, Keele BF.

PLoS Pathog. 2019 Apr 3;15(4):e1007632. doi: 10.1371/journal.ppat.1007632. eCollection 2019 Apr.

29.

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.

LaBranche CC, McGuire AT, Gray MD, Behrens S, Chen X, Zhou T, Sattentau QJ, Peacock J, Eaton A, Greene K, Gao H, Tang H, Perez LG, Saunders KO, Kwong PD, Mascola JR, Haynes BF, Stamatatos L, Montefiori DC.

PLoS Pathog. 2019 Mar 26;15(3):e1007646. doi: 10.1371/journal.ppat.1007646. eCollection 2019 Mar.

30.

Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual.

Krebs SJ, Kwon YD, Schramm CA, Law WH, Donofrio G, Zhou KH, Gift S, Dussupt V, Georgiev IS, Schätzle S, McDaniel JR, Lai YT, Sastry M, Zhang B, Jarosinski MC, Ransier A, Chenine AL, Asokan M, Bailer RT, Bose M, Cagigi A, Cale EM, Chuang GY, Darko S, Driscoll JI, Druz A, Gorman J, Laboune F, Louder MK, McKee K, Mendez L, Moody MA, O'Sullivan AM, Owen C, Peng D, Rawi R, Sanders-Buell E, Shen CH, Shiakolas AR, Stephens T, Tsybovsky Y, Tucker C, Verardi R, Wang K, Zhou J, Zhou T, Georgiou G, Alam SM, Haynes BF, Rolland M, Matyas GR, Polonis VR, McDermott AB, Douek DC, Shapiro L, Tovanabutra S, Michael NL, Mascola JR, Robb ML, Kwong PD, Doria-Rose NA.

Immunity. 2019 Mar 19;50(3):677-691.e13. doi: 10.1016/j.immuni.2019.02.008. Epub 2019 Mar 12.

PMID:
30876875
31.

Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages.

Corbett KS, Moin SM, Yassine HM, Cagigi A, Kanekiyo M, Boyoglu-Barnum S, Myers SI, Tsybovsky Y, Wheatley AK, Schramm CA, Gillespie RA, Shi W, Wang L, Zhang Y, Andrews SF, Joyce MG, Crank MC, Douek DC, McDermott AB, Mascola JR, Graham BS, Boyington JC.

MBio. 2019 Feb 26;10(1). pii: e02810-18. doi: 10.1128/mBio.02810-18.

32.

Improvement of antibody functionality by structure-guided paratope engraftment.

Liu Q, Lai YT, Zhang P, Louder MK, Pegu A, Rawi R, Asokan M, Chen X, Shen CH, Chuang GY, Yang ES, Miao H, Wang Y, Fauci AS, Kwong PD, Mascola JR, Lusso P.

Nat Commun. 2019 Feb 13;10(1):721. doi: 10.1038/s41467-019-08658-4.

33.

Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses.

Kanekiyo M, Joyce MG, Gillespie RA, Gallagher JR, Andrews SF, Yassine HM, Wheatley AK, Fisher BE, Ambrozak DR, Creanga A, Leung K, Yang ES, Boyoglu-Barnum S, Georgiev IS, Tsybovsky Y, Prabhakaran MS, Andersen H, Kong WP, Baxa U, Zephir KL, Ledgerwood JE, Koup RA, Kwong PD, Harris AK, McDermott AB, Mascola JR, Graham BS.

Nat Immunol. 2019 Mar;20(3):362-372. doi: 10.1038/s41590-018-0305-x. Epub 2019 Feb 11. Erratum in: Nat Immunol. 2019 Apr 12;:.

34.

Preparing for the Next Influenza Pandemic: The Development of a Universal Influenza Vaccine.

Crank MC, Mascola JR, Graham BS.

J Infect Dis. 2019 Apr 8;219(Supplement_1):S107-S109. doi: 10.1093/infdis/jiz043. No abstract available.

PMID:
30715413
35.

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.

Gaudinski MR, Coates EE, Novik L, Widge A, Houser KV, Burch E, Holman LA, Gordon IJ, Chen GL, Carter C, Nason M, Sitar S, Yamshchikov G, Berkowitz N, Andrews C, Vazquez S, Laurencot C, Misasi J, Arnold F, Carlton K, Lawlor H, Gall J, Bailer RT, McDermott A, Capparelli E, Koup RA, Mascola JR, Graham BS, Sullivan NJ, Ledgerwood JE; VRC 608 Study team.

Lancet. 2019 Mar 2;393(10174):889-898. doi: 10.1016/S0140-6736(19)30036-4. Epub 2019 Jan 24.

PMID:
30686586
36.

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.

Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B.

Cell Host Microbe. 2019 Jan 9;25(1):59-72.e8. doi: 10.1016/j.chom.2018.12.001. Erratum in: Cell Host Microbe. 2019 Aug 14;26(2):296.

37.

Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry.

Lai YT, Wang T, O'Dell S, Louder MK, Schön A, Cheung CSF, Chuang GY, Druz A, Lin B, McKee K, Peng D, Yang Y, Zhang B, Herschhorn A, Sodroski J, Bailer RT, Doria-Rose NA, Mascola JR, Langley DR, Kwong PD.

Nat Commun. 2019 Jan 3;10(1):47. doi: 10.1038/s41467-018-07851-1.

38.

Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier.

Bonsignori M, Scott E, Wiehe K, Easterhoff D, Alam SM, Hwang KK, Cooper M, Xia SM, Zhang R, Montefiori DC, Henderson R, Nie X, Kelsoe G, Moody MA, Chen X, Joyce MG, Kwong PD, Connors M, Mascola JR, McGuire AT, Stamatatos L, Medina-Ramírez M, Sanders RW, Saunders KO, Kepler TB, Haynes BF.

Immunity. 2018 Dec 18;49(6):1162-1174.e8. doi: 10.1016/j.immuni.2018.10.015. Epub 2018 Dec 11.

39.

Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation.

Guzzo C, Zhang P, Liu Q, Kwon AL, Uddin F, Wells AI, Schmeisser H, Cimbro R, Huang J, Doria-Rose N, Schmidt SD, Dolan MA, Connors M, Mascola JR, Lusso P.

MBio. 2018 Dec 11;9(6). pii: e00955-18. doi: 10.1128/mBio.00955-18.

40.

Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge.

Welles HC, Jennewein MF, Mason RD, Narpala S, Wang L, Cheng C, Zhang Y, Todd JP, Lifson JD, Balazs AB, Alter G, McDermott AB, Mascola JR, Roederer M.

PLoS Pathog. 2018 Dec 5;14(12):e1007395. doi: 10.1371/journal.ppat.1007395. eCollection 2018 Dec.

41.

Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition.

Chuang GY, Zhou J, Acharya P, Rawi R, Shen CH, Sheng Z, Zhang B, Zhou T, Bailer RT, Dandey VP, Doria-Rose NA, Louder MK, McKee K, Mascola JR, Shapiro L, Kwong PD.

Structure. 2019 Jan 2;27(1):196-206.e6. doi: 10.1016/j.str.2018.10.007. Epub 2018 Nov 21.

42.

Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4.

Stewart-Jones GBE, Chuang GY, Xu K, Zhou T, Acharya P, Tsybovsky Y, Ou L, Zhang B, Fernandez-Rodriguez B, Gilardi V, Silacci-Fregni C, Beltramello M, Baxa U, Druz A, Kong WP, Thomas PV, Yang Y, Foulds KE, Todd JP, Wei H, Salazar AM, Scorpio DG, Carragher B, Potter CS, Corti D, Mascola JR, Lanzavecchia A, Kwong PD.

Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):12265-12270. doi: 10.1073/pnas.1811980115. Epub 2018 Nov 12.

43.

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.

LaBranche CC, McGuire AT, Gray MD, Behrens S, Kwong PDK, Chen X, Zhou T, Sattentau QJ, Peacock J, Eaton A, Greene K, Gao H, Tang H, Perez LG, Chen X, Saunders KO, Kwong PD, Mascola JR, Haynes BF, Stamatatos L, Montefiori DC.

PLoS Pathog. 2018 Nov 5;14(11):e1007431. doi: 10.1371/journal.ppat.1007431. eCollection 2018 Nov. Erratum in: PLoS Pathog. 2019 Mar 26;15(3):e1007646.

44.

Limited anti-HIV neutralizing antibody breadth and potency before and after HIV superinfection in Danish men who have sex with men.

Redd AD, Helleberg M, Sievers M, Schmidt SD, Doria-Rose NA, Bruno D, Traeger S, Martens C, Fonager J, Kronborg G, Packman Z, Mascola JR, Porcella SF, Gerstoft J, Quinn TC.

Infect Dis (Lond). 2019 Jan;51(1):56-61. doi: 10.1080/23744235.2018.1500708. Epub 2018 Oct 14.

PMID:
30317905
45.

Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation.

Johnson EL, Doria-Rose NA, Gorman J, Bhiman JN, Schramm CA, Vu AQ, Law WH, Zhang B, Bekker V, Abdool Karim SS, Ippolito GC, Morris L, Moore PL, Kwong PD, Mascola JR, Georgiou G.

Nat Commun. 2018 Oct 8;9(1):4136. doi: 10.1038/s41467-018-06424-6.

46.

Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies.

Duan H, Chen X, Boyington JC, Cheng C, Zhang Y, Jafari AJ, Stephens T, Tsybovsky Y, Kalyuzhniy O, Zhao P, Menis S, Nason MC, Normandin E, Mukhamedova M, DeKosky BJ, Wells L, Schief WR, Tian M, Alt FW, Kwong PD, Mascola JR.

Immunity. 2018 Aug 21;49(2):301-311.e5. doi: 10.1016/j.immuni.2018.07.005. Epub 2018 Jul 31.

47.

Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV.

Dingens AS, Acharya P, Haddox HK, Rawi R, Xu K, Chuang GY, Wei H, Zhang B, Mascola JR, Carragher B, Potter CS, Overbaugh J, Kwong PD, Bloom JD.

PLoS Pathog. 2018 Jul 5;14(7):e1007159. doi: 10.1371/journal.ppat.1007159. eCollection 2018 Jul.

48.

Interdomain Stabilization Impairs CD4 Binding and Improves Immunogenicity of the HIV-1 Envelope Trimer.

Zhang P, Gorman J, Geng H, Liu Q, Lin Y, Tsybovsky Y, Go EP, Dey B, Andine T, Kwon A, Patel M, Gururani D, Uddin F, Guzzo C, Cimbro R, Miao H, McKee K, Chuang GY, Martin L, Sironi F, Malnati MS, Desaire H, Berger EA, Mascola JR, Dolan MA, Kwong PD, Lusso P.

Cell Host Microbe. 2018 Jun 13;23(6):832-844.e6. doi: 10.1016/j.chom.2018.05.002.

49.

Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.

Xu K, Acharya P, Kong R, Cheng C, Chuang GY, Liu K, Louder MK, O'Dell S, Rawi R, Sastry M, Shen CH, Zhang B, Zhou T, Asokan M, Bailer RT, Chambers M, Chen X, Choi CW, Dandey VP, Doria-Rose NA, Druz A, Eng ET, Farney SK, Foulds KE, Geng H, Georgiev IS, Gorman J, Hill KR, Jafari AJ, Kwon YD, Lai YT, Lemmin T, McKee K, Ohr TY, Ou L, Peng D, Rowshan AP, Sheng Z, Todd JP, Tsybovsky Y, Viox EG, Wang Y, Wei H, Yang Y, Zhou AF, Chen R, Yang L, Scorpio DG, McDermott AB, Shapiro L, Carragher B, Potter CS, Mascola JR, Kwong PD.

Nat Med. 2018 Jun;24(6):857-867. doi: 10.1038/s41591-018-0042-6. Epub 2018 Jun 4.

50.

HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure.

Kwong PD, Mascola JR.

Immunity. 2018 May 15;48(5):855-871. doi: 10.1016/j.immuni.2018.04.029. Review.

Supplemental Content

Loading ...
Support Center